![Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer](https://ala.associates/wp-content/uploads/2022/02/PE-Gerard-Biomunex.jpg)
![Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer](https://ala.associates/wp-content/uploads/2022/02/PE-Gerard-Biomunex.jpg)
![Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis](https://ala.associates/wp-content/uploads/2022/01/Irina-Gbalou-SynHelix-1080x675.jpg)
Univercells acquires SynHelix, entering into synthetic biology and the race to next-generation DNA synthesis
![Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting](https://ala.associates/wp-content/uploads/2021/11/VISUEL-TTO__0-e1637757456197.png)
Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting
![Robocath and Rennes University Hospital launch co-development research program into treatment of strokes in partnership with Philips France](https://ala.associates/wp-content/uploads/2021/07/photo-illustration-RS-1080x675.jpg)
Robocath and Rennes University Hospital launch co-development research program into treatment of strokes in partnership with Philips France
![Yposkesi accueille le groupe SK comme nouvel actionnaire majoritaire à son capital et noue ainsi un solide partenariat industriel de croissance](https://ala.associates/wp-content/uploads/2021/03/CAM01NEW-scaled-1-1080x675.jpg)
Yposkesi accueille le groupe SK comme nouvel actionnaire majoritaire à son capital et noue ainsi un solide partenariat industriel de croissance
![Noventure signs exclusive license agreement for innovative food supplement EPA3G](https://ala.associates/wp-content/uploads/2021/02/Logo_Noventure.jpg)
Noventure signs exclusive license agreement for innovative food supplement EPA3G
• EPA3G a unique, patented emulsion of high purity EPA, in drinkable single sachet – containing daily dose of 3g
• Deal gives Noventure licensing rights in over 50 countries
• Agreement signed with global partner Azur Global Nutrition
![Sebia enters into license agreement with Erasmus MC and Radboudumc to provide minimal residual disease test from serum samples of multiple myeloma patients](https://ala.associates/wp-content/uploads/2020/12/logos-1080x675.png)
Sebia enters into license agreement with Erasmus MC and Radboudumc to provide minimal residual disease test from serum samples of multiple myeloma patients
![Amolyt Pharma lance une collaboration de recherche avec PeptiDream](https://ala.associates/wp-content/uploads/2020/12/1-1-960x675.jpg)
Amolyt Pharma lance une collaboration de recherche avec PeptiDream
![Banook Group partners with Stefanini Group to expand support services](https://ala.associates/wp-content/uploads/2020/11/202011-PR_Stefanini-1080x675.png)
Banook Group partners with Stefanini Group to expand support services
![Vygon signs exclusive agreement with Medovate to distribute regional anaesthesia device](https://ala.associates/wp-content/uploads/2020/10/Exclusive-Distributor-Vygon-1080x675.png)